An advanced in situ nanovaccine, utilizing layered double hydroxides as a vehicle for cyclic GMP‐AMP (cGAMP), a stimulator of IFN genes (STING) agonist, and adsorbed TAAs, has been reported to significantly modulate tumor immune microenvironment and augment the efficacy of anti‐PD‐L1 immunotherapies for HCC, offering a promising strategy for in situ cancer vaccination [578]. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.